Biodegradable Particle Vaccine Formulations for Th1/Th2 Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing immune responses against pathogens and diseases often fail to effectively differentiate between Th1 and Th2 cell responses, which are crucial for determining the outcome of immune reactions and defense mechanisms against different types of pathogens.
Innovation Solution
Biodegradable particles with an average diameter of 0.5-10 um, formed from polymeric or non-polymeric materials, are used to stimulate an immune response, optionally including adjuvants and apoptosis inhibitors, administered to induce either Th1 or Th2 cell immunity, and are designed to enhance weight gain and feed conversion rates in animals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to induce immune responses, then immune protection is provided, but the ability to effectively differentiate between Th1 and Th2 cell responses is insufficient
Solution Approach 1:
The patent changes the physical parameter of particle size (0.5-10 μm) and chemical composition (biodegradable polymers like PLGA, PCL, PLA) of the vaccine formulation to selectively modulate the immune response. These parameter changes enable differentiation between Th1 and Th2 responses by controlling particle degradation rate, surface area, and interaction with immune cells, thereby achieving both precise differentiation and effective immune protection.
2Reliability
If biodegradable particles with specific size range (0.5-10 um) are used, then Th1 cell immune response is effectively induced, but the complexity of formulation and administration increases
Solution Approach 1:
The patent employs composite materials consisting of biodegradable polymers (PLGA, PCL, or PLA) combined with specific adjuvants (CpG oligonucleotides, saponin, or alum) within a defined particle size range. This composite approach enables reliable Th1 response induction by synergistically combining the properties of different materials: the polymer provides controlled degradation and sustained release, while the adjuvants enhance antigen presentation and T-cell activation.
Solution Approach 2:
The patent specifies precise parameter ranges for particle size (0.5-10 μm) and polymer composition to optimize Th1 response while managing formulation complexity. By controlling these parameters, the formulation achieves reliable immune induction without requiring overly complex manufacturing processes, as the spray-drying method can readily produce particles within this size range.
3Power
If particles with larger surface area are used to enhance immune stimulation, then immune response intensity increases, but the dosing precision and control become more difficult
Solution Approach 1:
The patent controls the particle size parameter (0.5-10 μm) to optimize the surface area-to-volume ratio, thereby achieving intense immune stimulation while maintaining dosing precision. This specific size range ensures sufficient surface area for immune cell interaction and antigen presentation, while the uniform size distribution achieved through spray-drying allows for precise dosing control and reproducible administration.
Data Source
Figure 1A
Figure 1B~1D
Figure 2A~2B
AI summary
Disclosed are compositions, kits, and methods for inducing an immune response against' an infection or a disease. The compositions typically include biodegradable particles having an average effective diameter of 0.5 - 20 μηι, and optionally the compositions include one or more of an adjuvant, an apopiosis inhibitor, and an antigen. The compositions, kits, and methods may be utilized to induce a cell-mediated response, such as a T- helper cell response., arid/or a humoral response against a pathogen or a disease. In some embodiments, the compositions, kits, and methods may be utilized to induce preferentially a Till response versus other types of immune responses such as a Th2 response.